NCT01841931View on ClinicalTrials.gov

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

NATerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine/Naloxone

Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn

Sponsors
All Listed Sponsors
lead

Maimonides Medical Center

OTHER